Background:
- Glioblastoma is an aggressive type of brain cancer that often resists treatment. TRC105 is
an experimental drug that blocks the growth of new blood vessels. It is being studied for
possible use in treating different kinds of cancer. Researchers want to see if TRC105 can be
used to treat glioblastoma that has not responded to standard treatments.
Objectives:
- To test the safety and effectiveness of TRC105 in adults who have glioblastoma that has not
responded to standard treatments.
Eligibility:
- Individuals at least 18 years of age who have glioblastoma that has not responded to
standard treatments.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Imaging studies and other tests will be used to study the
tumor before the start of treatment.
- Participants will have 28-day (4-week) cycles of treatment.
- Participants will have TRC105 intravenously once a week. The first infusion will take
about 4 hours. The length of time needed for the infusion may be slowly reduced if it is
well tolerated.
- At the end of the first cycle (the first 4 weeks), the imaging studies will be repeated
before continuing TRC105.
- Participants will take TRC105 for as long as the tumor does not grow and the side
effects are not too severe. They will have imaging studies at the end of every cycle to
evaluate the tumor.